文献速递母胎医学产科

在丹麦临床环境中采用游离DNA进行条件性早孕期非整倍体筛查

Contingent first-trimester screening for aneuploidies with cell-free DNA in a Danish clinical setting.
PubMed 文献 · Ultrasound Obstet Gynecol · 2018-03-04

该研究在丹麦两家医院连续纳入早孕期联合筛查21三体风险≥1/1000的单胎孕妇,比较两种筛查策略:传统策略对风险≥1/300者转诊侵入性检测,条件性策略对风险≥1/100者转诊侵入性检测、对风险1/100至1/1000者转诊cfDNA检测。结果显示两种策略对21三体的敏感性均为100%,条件性策略特异性显著提高。

要点

  • 条件性筛查策略对21三体敏感性100%,与传统策略相同。
  • 条件性策略特异性98.8%,显著高于传统策略的97.0%(P<0.0001)。
  • cfDNA检测性染色体非整倍体假阳性率为1.2%。

核心结论

  • 在联合筛查效率高的临床环境中,条件性筛查(风险≥1/100者转诊侵入性检测,风险1/100至1/1000者转诊cfDNA检测)与传统筛查(风险≥1/300者转诊侵入性检测)相比,对21三体、18三体和13三体的敏感性相同,但特异性显著提高。
  • 实施条件性筛查可在不损失敏感性的情况下显著减少侵入性检测数量。

研究设计与样本

  • 研究于2014年8月至2015年5月在丹麦两家医院连续招募早孕期联合筛查21三体风险≥1/1000的单胎孕妇。
  • 联合筛查基于孕妇年龄、颈项透明层厚度以及妊娠相关血浆蛋白A(PAPP-A)和β-人绒毛膜促性腺激素(β-hCG)水平。
  • cfDNA检测分析21三体、18三体、13三体和性染色体非整倍体风险,且对联合筛查评估和核型结果设盲。
  • 妊娠结局及产前产后核型来自丹麦胎儿医学数据库。

主要发现

  • 6449名接受联合筛查风险评估的孕妇中,869名(13.5%)21三体风险≥1/1000,其中597名纳入cfDNA检测。
  • 纳入cfDNA检测的597名孕妇中,检出15例21三体、1例18三体和2例13三体。
  • 传统策略对21三体检出敏感性100%,条件性策略亦为100%;特异性从传统策略的97.0%显著提高至条件性策略的98.8%(P<0.0001)。
  • 对21三体、18三体和13三体的合并检出敏感性从传统策略的94.4%提高至条件性策略的100%,置信区间重叠;特异性从传统策略的97.1%显著提高至条件性策略的98.9%(P<0.0001)。
  • cfDNA检测将7例妊娠归类为性染色体非整倍体高风险,但染色体分析结果不一致,对应假阳性率1.2%。

临床怎么用

  • 作者结论认为,在联合筛查效率高的临床环境中实施条件性筛查可显著减少侵入性检测数量而不损失敏感性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The primary aim of this study was to compare the screening performance for trisomy 21 (T21) between combined first-trimester screening (cFTS) with referral for invasive testing at a T21 risk ≥ 1 in 300, and contingent screening consisting of referral for invasive testing at a cFTS-T21 risk ≥ 1 in 100 and referral for cell-free DNA (cfDNA) testing at a cFTS-T21 risk between 1 in 100 and 1 in 1000. Secondary aims were to compare the incidence of fetuses diagnosed with trisomy 18 (T18), trisomy 13 (T13) or sex chromosome aneuploidy, and examine the association between fetal fraction of cfDNA in maternal blood and maternal/fetal characteristics. METHODS: Women with a singleton pregnancy and a cFTS-T21 risk of ≥ 1 in 1000 were recruited consecutively from two Danish hospitals between August 2014 and May 2015. First-trimester combined screening was based on maternal age, nuchal translucency thickness and levels of pregnancy-associated plasma protein A (PAPP-A) and β-human chorionic gonadotropin (β-hCG). Blood samples for cfDNA testing were analyzed for risks of T21, T18, T13 and sex chromosomal aneuploidies. cfDNA analysis was conducted blinded to the cFTS assessment and karyotype results. Pregnancy outcomes and pre- and postnatal karyotypes were obtained from the Danish Fetal Medicine Database. RESULTS: Among 6449 women who underwent cFTS risk assessment, 869 (13.5%) had a T21 risk of ≥ 1 in 1000 and 597 were included for cfDNA testing. Among these, there were 15 cases of T21, one case of T18 and two cases of T13. The sensitivity for detection of T21 was 100% using both screening strategies, while specificity increased significantly (P < 0.0001) from 97.0% using the cFTS strategy to 98.8% using the contingent approach. The sensitivity for detection of T21, T18 and T13 increased from 94.4% using the cFTS strategy to 100% using the contingent approach, with overlapping CIs, while specificity increased significantly (P < 0.0001) from 97.1% for cFTS to 98.9% for the contingent strategy. Seven pregnancies were categorized as being at increased risk of a sex chromosomal aneuploidy by cfDNA testing but chromosome analysis was discordant, corresponding to a false-positive rate of 1.2%. The fetal fraction decreased significantly with increasing maternal weight and increased significantly with the level of β-hCG and PAPP-A and among female fetuses, in both univariate and multivariate analyses. CONCLUSIONS: In a clinical setting with efficient cFTS, contingent screening offering women with a cFTS risk of ≥ 1 in 100 an invasive test and women with a risk from 1 in 100 to 1 in 1000 a cfDNA test had the same sensitivity for T21, T18 and T13, but significantly increased specificity, when compared with offering an invasive test to all women with a risk of ≥ 1 in 300. Implementing contingent screening would therefore reduce significantly the number of invasive tests performed at no loss of sensitivity. Copyright © 2017 ISUOG. Published by John Wiley & Sons Ltd.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Miltoft CB, Rode L, Ekelund CK, et al. Contingent first-trimester screening for aneuploidies with cell-free DNA in a Danish clinical setting. Ultrasound Obstet Gynecol. 2018. PMID: 28640470. doi:10.1002/uog.17562

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。